Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome

[Business Wire] – Gilead Sciences, Inc. today announced results from a Phase 1 clinical trial of GS-6615, an investigational, selective late sodium current inhibitor, showing a shortening of the QTc interval in patients with long QT-3 syndrome. more

View todays social media effects on GILD

View the latest stocks trending across Twitter. Click to view dashboard

See who Gilead is hiring next, click here to view